Loading…
Loading…
Amgen reached a $74 million settlement of a lawsuit accusing the biotechnology company of waiting too long to disclose that it might owe the Internal Revenue Service $10.7 billion for underreporting six years of taxes.
Andra AP fonden cut its holdings in Amgen Inc. (NASDAQ: AMGN) by 18.9% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 50,366 shares of the medical research company's stock after selling 11,734 shares during the quarter. Andra AP fonden's holdings in
On July 20, 2026, we present a DCF analysis for Amgen Inc (AMGN), a company that has shown strong price performance over the past year, with a 26.5% increase. T
Dimensional Fund Advisors LP lifted its position in shares of Amgen Inc. (NASDAQ: AMGN) by 2.3% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 3,304,344 shares of the medical research company's stock after buying an additional 73,365 shares during the period. Dimensional Fund Advisors LP
Boston Common Asset Management LLC reduced its stake in shares of Amgen Inc. (NASDAQ: AMGN) by 10.4% in the first quarter, according to its most recent filing with the SEC. The fund owned 29,640 shares of the medical research company's stock after selling 3,458 shares during the period. Boston Common Asset Management LLC's
Decker Wealth Management LLC purchased a new stake in Amgen Inc. (NASDAQ: AMGN) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 15,840 shares of the medical research company's stock, valued at approximately $5,573,000. Other hedge funds have also bought
The FDA's approval of Merck (NYSE:MRK | MRK Price Prediction) enlicitide decanoate, marketed as Lipfendra, marks the first once-daily oral PCSK9 inhibitor cleared for adults with high LDL cholesterol, including heterozygous familial hypercholesterolemia.
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for AMGN and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.